Replies to post #82497 on Elite Pharmaceuticals Inc (ELTP)

[Pharma Sleuth]

So you didn't answer either question. The shares were dispersed a long time ago. There is no reporting so saying they were dispersed has nothing to do with whether or not they sold any. The only people that know are them really. From a long time ago.

Epic can only sell a very small % of their holdings anyway due to SEC rules which I believe someone explained to you when the claims of all this selling was made over and over.

So in other words, while the claims of selling of Epic dispersed shares has been made for a long long time, there is no proof. But the claim goes on infinity.

Say what product did you say was going to be announced in 10 days?

[Couch]

Selling shares and Elite doesn't have enough money for a 505b2 study.....let alone 3 LOL LOL.... I agree Nasrat Hakim ~~~ THE CLOSER ~~~ bought 11 Million Shares on the open market and loaned the company $1 Million Dollars out of his own pocket.......and how many shares did Jerry agree to buy recently.........but hey here is what is really important! $$$$$$$$$

http://www.elitepharma.com/investor_relations.asp?goto=370

Northvale, New Jersey, Thursday, December 05, 2013: Elite Pharmaceuticals, Inc. ("Elite" or the “Company") ("Elite”) (OTCBB: ELTP) announced today the first dosing of a pilot bioequivalence study in healthy volunteers for ELI-201, the Company’s twice daily abuse deterrent oxycodone/naltrexone product.

Elite has met the goal of starting the bio study for ELI-201 in December. A pivotal bioequivalence study for a second abuse deterrent product is scheduled to begin dosing in January 2014, and the pivotal bioequivalence study for ELI-201 is scheduled to begin dosing in March 2014. The bioequivalence studies for these opioid abuse deterrent products are being conducted under the direction of Camargo Pharmaceutical Services.

“The start of the ELI-201 pilot study marks a major milestone for the development of products utilizing our proprietary abuse deterrent technology,” said Nasrat Hakim, Elite’s President and CEO. “I am extremely pleased with the progress Elite has made with the development of this technology. We have set several initiatives in motion and all of our research and development projects are on or ahead of schedule. We appreciate the guidance and expertise that has been provided by Camargo and look forward to this next phase for the Company.”